SNPHF लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 23:33):

Stats
आज की मात्रा	31.00
औसत मात्रा	42.00
बाजार मूल्य	3.37B
EPS	$24.13 ( 2023-11-06 )
Last Dividend	$0.121 ( 2023-03-30 )
Next Dividend	$0 ( N/A )
P/E	19.29
ATR14	$0 (0.00%)

Santen Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Santen Pharmaceutical वित्तीय

Annual	2023
राजस्व:	$279.04B
सकल लाभ:	$166.09B (59.52 %)
EPS:	$-38.58

FY	2023
राजस्व:	$279.04B
सकल लाभ:	$166.09B (59.52 %)
EPS:	$-38.58

FY	2022
राजस्व:	$266.26B
सकल लाभ:	$156.59B (58.81 %)
EPS:	$68.07

FY	2021
राजस्व:	$249.61B
सकल लाभ:	$151.38B (60.65 %)
EPS:	$17.09

Financial Reports:

No articles found.

Santen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.111 (N/A)	$0 (N/A)	$0.121 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Santen Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.85 - Stable (3.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0980	2014-03-27
Last Dividend	$0.121	2023-03-30
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$2.40	--
Avg. Dividend % Per Year	0.00%	--
Score	3.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.85
Div. Directional Score	7.99	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NXGPY	Ex Dividend Knight	2023-07-06	Semi-Annually	0.00%
DANOY	Ex Dividend Junior	2023-05-05	Annually	0.00%
TLGHY	Ex Dividend Junior	2023-05-03	Annually	0.00%
IMBBY	Ex Dividend Knight	2023-08-17	Quarterly	0.00%
BICEY	Ex Dividend Knight	2023-05-24	Annually	0.00%
PSMMY	Ex Dividend Junior	2023-10-12	Semi-Annually	0.00%
ENGGY	Ex Dividend Knight	2023-07-03	Semi-Annually	0.00%
UOVEY	Ex Dividend Knight	2023-08-04	Annually	0.00%
KNRRY	Ex Dividend Knight	2023-05-08	Annually	0.00%
CCOEF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0918	1.500	8.16	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0648	1.200	7.84	9.41	[0 - 0.3]
returnOnEquityTTM	0.0924	1.500	-0.0848	-0.127	[0.1 - 1]
payoutRatioTTM	0.429	-1.000	5.71	-5.71	[0 - 1]
currentRatioTTM	2.46	0.800	2.72	2.17	[1 - 3]
quickRatioTTM	1.841	0.800	3.88	3.10	[0.8 - 2.5]
cashRatioTTM	0.897	1.500	6.13	9.19	[0.2 - 2]
debtRatioTTM	0.0786	-1.500	8.69	-10.00	[0 - 0.6]
interestCoverageTTM	20.13	1.000	3.66	3.66	[3 - 30]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.113	-1.500	9.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.606	1.000	3.24	3.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.143	1.000	9.14	9.14	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.706	0.800	8.63	6.90	[0.5 - 2]
Total Score				11.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.69	1.000	8.21	0	[1 - 100]
returnOnEquityTTM	0.0924	2.50	-0.0545	-0.127	[0.1 - 1.5]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0150	1.500	9.63	0	[0 - 0.4]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.429	1.500	5.71	-5.71	[0 - 1]
pegRatioTTM	-0.000754	1.500	-3.34	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.225	1.000	6.86	0	[0.1 - 0.5]
Total Score				4.85

Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.